A validated model of serum anti-Mullerian hormone from conception to menopause
T W Kelsey, P Wright, S M Nelson, R A Anderson, W H B Wallace

TL;DR
This study presents the first validated model of serum anti-Mullerian hormone levels from conception to menopause, revealing key inflection points and providing normative data to improve ovarian reserve assessment.
Contribution
The paper develops and validates the first comprehensive model of AMH levels across the entire female lifespan, incorporating new data and identifying critical age-related changes.
Findings
AMH peaks at age 24.5 years
Neonatal and pre-pubertal peaks confirmed
AMH variation is 34% explained by age
Abstract
Background: Anti-Mullerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopause has not been reported. Methodology/Principal Findings: By searching the published literature for AMH concentrations in healthy pre-menopausal females, and using our own data (combined n = 3,260) we have generated and robustly validated the first model of AMH concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential pre-pubertal peak. Our model allows us to generate…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOvarian function and disorders · Reproductive Biology and Fertility · Sperm and Testicular Function
